Kit for predicting lung cancer metastasis, and usage method of kit

Abstract

The invention relates to a kit for predicting lung cancer metastasis, and a usage method of the kit. The kit comprises a DNA library kit which comprises probes of multiple genes, and the multiple genes comprise: high-risk genes: BRCA1, BRCA2, PALB2, ATM, ATR, MUTYH, EMSY, ERCC4, RAD51, PARP1 and XRCC1; and low-risk genes: ATRX, BRIP1, FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, FANCO, FANCP, MDM2, MDM4, MLH1, NPM1, PP2R1A, PRKDC, RAD50, STAG2, XRCC5, XRCC6. Through performing related mutation detection to the related genes of DNA repair system signal paths, lung cancer metastasis can be rapidly and conveniently judged and predicted by combining a special rating mechanism.

Description

technical field [0001] The invention relates to a kit for predicting lung cancer metastasis and its application method. Background technique [0002] Tumor metastasis means that tumor cells invade lymphatic vessels from the original site, blood vessels or other pathways are taken to it to continue to grow, and form a tumor of the same type as the tumor at the primary site. This process is called metastasis, and the formed tumor becomes a metastatic tumor or metastatic cancer. Metastasis is a hallmark of malignant tumors. Metastasis of different organs can occur in the late stage of lung cancer, which can cause corresponding symptoms, often bring great pain to patients, and even threaten their lives. The median survival time for brain metastases from lung cancer is only 4 months. A small number of patients have a relatively long survival period, especially those who are effective in targeted drug therapy. Early diagnosis of lung cancer metastasis has great clinical value,...

AI Technical Summary

Problems solved by technology

Diagnosis of liver metastases from lung cancer includes: (1) Abdominal color ultrasound, which is the first choice for clinical diagnosis of liver metastases of lung cancer and follow-up after treatment. Generally, liver metastases with a size of 1-2 cm can be visualized, and the overall clinical diagnosis accuracy rate can reach up to 90%; (2) Abdominal computed tomography (CT), which has become a routine examination method for the diagnosis of liver metastases from lung cancer, can detect metastatic foci of 1-2 cm or smaller, and its sensitivity can exceed 90%; (3) In magnetic resonance imaging (MRI), liver metastases from lung cancer manifest as multiple or single lesions with clear borders, uniform or unequal signal intensity, and "target sign" or "bright ring sign". CT is similar; (4) Selective celiac artery or hepatic arteriography can often show liver metastases with a size of 1 cm or less, and it is difficult to determine the nature of intrahepatic space-occupying. Selective arteriography may be considered for patients with satellite metastatic cancer; (5) Positron emission tomography (PET). The tomographic images obtained by PET mainly reflect the metabolic information of tissues / cells, which can directly analyze the physiological and biochemical parameters of the human body. Metabolism research, it is possible to find tumors in the early stage of tumor occurrence, that is, before its pathological changes, but because of its high price, it cannot be widely used at present, and can only be used as a special inspection method

In clinical practice, the current mainstream is to use medical imaging to diagnose lung cancer metastasis, which has three disadvantages: (1) Imaging indicators are not objective enough, and the identification of some tiny tumor foci is artificial, requiring experienced doctors To identify; (2) The tumor metastases identified by imaging, confirmed that the tumor has metastasized and grown to a certain extent, is already in the late stage of metastasis for the patient, which is not conducive to early treatment; (3) Some tests are expensive

Images